Sage Therapeutics Inc
What Are Sage Therapeutics’ Receptor-Based Products?
Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders.
Key Risks Facing Marinus Pharmaceuticals in December 2017
Since inception in 2003, Marinus Pharmaceuticals (MRNS) has focused on the development of ganaxalone.
Sage’s Brexanolone IV: FDA Grants Priority Review
On May 30, Sage Therapeutics announced that the FDA accepted the new drug application for Brexanolone IV.
Sage Therapeutics: Analysts’ Estimates and Recommendations
On July 12, analysts forecast a Q2 net loss of $85.7 million for Sage Therapeutics (SAGE) and a net loss of $377.6 million in fiscal 2018.
SAGE Therapeutics’ Strategic Collaboration with Shionogi
On June 13, SAGE Therapeutics announced a strategic collaboration with Shionogi & Company for the development and commercialization of the drug SAGE-217.
SAGE Therapeutics’ Stock Performance and Estimates in June
SAGE Therapeutics’ stock price has risen nearly 111.5% in the last 12 months.
Sage Therapeutics: Results from the Phase 3 ROBIN Trial
On January 7, Sage Therapeutics presented the results of the Phase 3 ROBIN trial. SAGE-217 met the clinical trial’s primary and secondary endpoints.
Sage Therapeutics’ Operational Performance
In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively.
Sage Therapeutics: Analyzing New Product Candidates
The Zulresso injection is Sage Therapeutics’ lead product candidate. The company has filed a new drug application.
Here Are the Key Products in Sage’s GABA Receptor Portfolio
Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.
A Look at Sage Therapeutics’ NMDA Receptor Portfolio
Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders.
How Does Sage Therapeutics’ Product Portfolio Look in September?
Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.
FDA Approves United Therapeutics’ Implantable System for Remodulin
Today, the FDA approved United Therapeutics’ (UTHR) new drug application for its Remodulin injection used in the Implantable System for Remodulin (or ISR).
Sage Therapeutics’ NMDA Receptor–Based Products
Sage Therapeutics developed SAGE-718, which targets the NMDA Receptor.
Sage Therapeutics’ GABA Receptor–Based Products
On June 12, Sage Therapeutics announced its expedited development plan for SAGE-217.
Ganaxalone Faces Stiff Competition from Other Drugs under Development
Marinus Pharmaceuticals (MRNS) has initiated a phase two study to test the feasibility of ganaxalone in patients suffering from refractory status epilepticus (or RSE). Data from this study is expected in 2018.
Why Ganaxalone Is a Promising Drug Candidate
Marinus Pharmaceuticals (MRNS) announced phase two results from its open-label study evaluating the efficacy of ganaxalone in patients suffering from CDKL5 deficiency disorder (or CDD) in September 2017.
What Are Sage Therapeutics’ GABA Receptor Products?
The products under development for the treatment of life-threatening central nervous system (or CNS) disorders in Sage Therapeutics’ (SAGE) portfolio are either based on GABA or NMDA receptor systems.
Brexanolone Could Strengthen Ligand’s Neurology Portfolio
Sage Therapeutics is also exploring Brexanolone in moderate and severe post-partum depression (or PPD) patients in two separate Phase 3 trials.
What Are IBB’s Holdings’ Moving Averages?
On May 27, 2016, 17% of the iShares Nasdaq Biotechnology ETF’s (IBB) stocks were trading above their 20-day moving averages.
iShares Nasdaq Biotechnology ETF (IBB) Had Strong Start to April
Celldex Therapeutics (CLDX) was the top performer among IBB holdings, rising 10.6% on April 4. The other top performers include Synergy Pharmaceuticals (SGYP) and Sage Therapeutics (SAGE)